Literature DB >> 17999914

Cystamine prevents ischemia-reperfusion injury by inhibiting polyamination of RhoA.

Dong-Myung Shin1, Jinmo Kang, Jongwon Ha, Heun-Soo Kang, Sang-Chul Park, In-Gyu Kim, Sang Joon Kim.   

Abstract

Transglutaminase2 (TGase2) activates Rho-associated kinase (ROCK), an important mediator of ischemia-reperfusion (IR) injury, through polyamination of RhoA. Cystamine, an oxidized dimer of cysteamine inhibits the transamidation activity of TGase2. We examined whether addition of cystamine to an organ preservation solution protects rat cardiomyocyte cells (H9C2) from cell death in IR injury. H9C2 cells were stored under hypoxic conditions at 4 degrees C in laboratory-made preservation solution (SNU) or SNU solution supplemented with cystamine (SNU-C1), and cell preservation in the two solutions was compared by measuring the release of lactate dehydrogenase. The cells were preserved more effectively in SNU-C1 than in SNU solution. Cystamine inhibited the intracellular activity of TGase2 which increased during cold storage or reoxygenation. The inhibition of TGase2 by cystamine reduced the polyamination of RhoA, the interaction between RhoA and ROCK2, and F-actin formation. Cystamine also prevented the activation of caspases during cold storage. These results suggest that addition of cystamine to the organ preservation solution significantly enhances cardiomyocytes preservation apparently by inhibiting TGase2-mediated RhoA-ROCK pathway and that TGase2 may play an important role in IR injury by regulating ROCK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999914     DOI: 10.1016/j.bbrc.2007.11.007

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Zachary Herrera; Megan Albertelli; Chaitan Khosla
Journal:  J Med Chem       Date:  2014-10-31       Impact factor: 7.446

Review 2.  Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.

Authors:  Manuela Basso; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

3.  Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death.

Authors:  Sung-Yup Cho; Eui Man Jeong; Jin-Haeng Lee; Hyo-Jun Kim; Jisun Lim; Chai-Wan Kim; Dong-Myung Shin; Ju-Hong Jeon; Kyungho Choi; In-Gyu Kim
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

4.  Pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1) gene is suppressed by transglutaminase 2 activation.

Authors:  Ayako Miura; Yuki Kambe; Kazuhiko Inoue; Hideki Tatsukawa; Takashi Kurihara; Martin Griffin; Soichi Kojima; Atsuro Miyata
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

5.  Transglutaminase 2 mediates transcriptional regulation through BAF250a polyamination.

Authors:  Hyo-Jun Kim; Jin-Haeng Lee; Sung-Yup Cho; Ju-Hong Jeon; In-Gyu Kim
Journal:  Genes Genomics       Date:  2021-02-08       Impact factor: 1.839

Review 6.  Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration.

Authors:  Trisha R Stankiewicz; Daniel A Linseman
Journal:  Front Cell Neurosci       Date:  2014-10-07       Impact factor: 5.505

7.  The role of Rho/Rho-kinase pathway and the neuroprotective effects of fasudil in chronic cerebral ischemia.

Authors:  Ya-Yun Yan; Xiao-Ming Wang; Yan Jiang; Han Chen; Jin-Ting He; Jing Mang; Yan-Kun Shao; Zhong-Xin Xu
Journal:  Neural Regen Res       Date:  2015-09       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.